Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lyme Disease - Overview
Lyme Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Lyme Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lyme Disease - Companies Involved in Therapeutics Development
Inovio Pharmaceuticals Inc
NovoBiotic Pharmaceuticals LLC
Valneva SE
Lyme Disease - Drug Profiles
azithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclol Antibody to Inhibit CRASP1 for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
desloratadine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit OspA for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lyme disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lyme disease vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Inhibit Outer Surface Protein A for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VLA-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lyme Disease - Dormant Projects
Lyme Disease - Product Development Milestones
Featured News & Press Releases
Jan 31, 2019: VALNEVA reports positive initial booster data and fil phase 1 data for its Lyme disease vaccine candidate
Dec 17, 2018: Valneva starts Phase ll trial of VLA15 to treat Lyme disease
Oct 25, 2018: VALNEVA receives positive feedback from EMA on its further development for Lyme disease vaccine VLA15
Jul 02, 2018: Valneva Announces Significant Progress of its Lyme Disease Vaccine Candidate
Mar 29, 2018: VALNEVA to Present on Lyme disease candidate VLA-15 at the 18th World Vaccine Congress in Washington, D.C.
Mar 19, 2018: VALNEVA Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15
Jul 24, 2017: VALNEVA Receives FDA Fast Track Desigtion for its Lyme Disease Vaccine Candidate VLA15
Dec 09, 2016: Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate
Jul 12, 2016: European Investment Bank Grants Valneva a EU25 Million Loan to Fund R&D Activities
Mar 24, 2016: VALNEVA to present at the 16th World Vaccine Congress in Washington D.C.
Jan 22, 2013: Agile Sciences Receives Grant From Bay Area Lyme Fund
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Lyme Disease, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development for Lyme Disease, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Lyme Disease - Pipeline by Inovio Pharmaceuticals Inc, H1 2019
Lyme Disease - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2019
Lyme Disease - Pipeline by Valneva SE, H1 2019
Lyme Disease - Dormant Projects, H1 2019